2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155568
    Anti-inflammatory agent 47 2925288-12-4
    Flo8 is a potent anti-inflammatory and antioxidant compound. Flo8 inhibits the release of intracellular reactive oxygen species (ROS) and nitric oxide (NO) and suppresses neuronal apoptotic by inhibiting inflammatory and apoptotic signaling pathways. Flo8 can be used for Parkinson's Disease (PD) research.
    Anti-inflammatory agent 47
  • HY-15556A
    GSK269962A hydrochloride 2095432-71-4 99.73%
    GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities.
    GSK269962A hydrochloride
  • HY-155572
    Nrf2 activator-8
    Nrf2 activator-8 (compound 10e) is a Nrf2 activator (EC50=37.9 nM). Nrf2 activator-8 exhibits remarkable antioxidant and anti-inflammatory effects in BV-2 microglial cells. Nrf2 activator-8 can significantly restore spatial memory deficits in a mouse model of lipopolysaccharide (LPS)-induced neuroinflammation.
    Nrf2 activator-8
  • HY-155593
    JNK-1-IN-2
    JNK-1-IN-2 (Compound c6) is a JNK-1 inhibitor (IC50: 33.5 nM). JNK-1-IN-2 also inhibits JNK-2 and JNK-3 with IC50s of 112.9 nM and 33.2 nM. JNK-1-IN-2 inhibits the phosphorylation of c-Jun. JNK-1-IN-2 reverses lung impairment. JNK-1-IN-2 can be used for research of pulmonary fibrosis.
    JNK-1-IN-2
  • HY-155597
    h-NTPDase8-IN-1 716358-51-9
    h-NTPDase8-IN-1 (compound 2d) is a sulfamoyl-benzamides based and selective inhibitor for h-NTPDases8 (IC50=0.28 μM). h-NTPDases8 is involved in a variety of physiological and pathological functions，such as thrombosis，diabetes，inflammation，and cancer.
    h-NTPDase8-IN-1
  • HY-155611
    Cathepsin C-IN-6
    Cathepsin C-IN-6 (compound 2) is a E-64c-hydrazideas based inhibitor of cathepsin C with anti-inflammatory activity. Cathepsin C-IN-6 inhibts activation of neutrophil elastase，exhibits potential efficacy in inflammatory diseases with high neutrophil load (e.g.，chronic obstructive pulmonary disease).
    Cathepsin C-IN-6
  • HY-155646
    Anti-inflammatory agent 48
    Anti-inflammatory agent 48 is an anti-inflammatory agent based on its role in inhibiting the NF-κB signaling pathway and activating HO-1 expression.
    Anti-inflammatory agent 48
  • HY-155680
    BET BD2-IN-1 2677039-24-4
    BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC50=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research.
    BET BD2-IN-1
  • HY-155692
    PDE4-IN-13
    PDE4-IN-13 is a PDE4 inhibitor with an IC50 of 1.56 μM. PDE4-IN-13 shows anti-inflammatory and antioxidant properties， and can be used for chronic obstructive pulmonary disease (COPD) research.
    PDE4-IN-13
  • HY-155699
    J27644 3033032-03-7
    J27644 is a potent HDAC inhibitor. J27644 mitigates TGF-β-induced pulmonary fibrosis.
    J27644
  • HY-155706
    MOR agonist-2 2833692-02-5
    MOR agonist-2 (compound 46) is a antagonist of D3R and agonist of MOR (Ki: 7.26 nM and 564 nM, respectively). MOR agonist-2 has the potential to produce analgesic effects through MOR partial agonism. MOR agonist-2 reduces opioid-misuse liability via D3R antagonism.
    MOR agonist-2
  • HY-155707
    MOR agonist-3
    MOR agonist-3 (Compound 84) is a D3R/MOR antagonist/partial agonist a(Ki 382 nM and 55.2 nM respectively). MOR agonist-3 has the potential to produce analgesic effects through MOR (μ-opioid receptor) (HY-149337) partial agonists and to reduce opioid abuse through D3R antagonists. MOR agonist-3 can be used in the treatment of inflammation and neuropathic pain research.
    MOR agonist-3
  • HY-155746
    JAK2-IN-9 2568842-26-0
    JAK2-IN-9 (Compound A8) is a selective JAK2 inhibitor (IC50: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs).
    JAK2-IN-9
  • HY-155753
    Anti-inflammatory agent 50
    Anti-inflammatory agent 50 (compound a1) is a Fusidic acid derivative with anti-inflammatory effects. Anti-inflammatory agent 50 inhibits inflammatory factor NO, IL-6 and TNF-α. Anti-inflammatory agent 50 alleviates acute lung injury by regulating inflammatory mediators and suppressing the MAPK, NF-κB and NLRP3 inflammasome signaling pathways.
    Anti-inflammatory agent 50
  • HY-155759
    HMGB1-IN-2
    HMGB1-IN-2 (compound 15) is an inhibitor of highly conserved nuclear protein (HMGB1), showing NO inhibitory effect with IC50 value of 20.2 μM in RAW264.7 cells. HMGB1-IN-2 (30 μM) decreases the level of IL-1 β, TNF-α, caspase-1 p20, inhibits the phosphorylation of NF-κB p65, exhibits anti-apoptotic activity. HMGB1-IN-2 (15 mg/kg; ip) relives kidney injury in septic acute kidney injury mouse. HMGB1-IN-2 inhibits Huh7 cells and A549 cells with IC50s of 77.0 μM, and 82.0 μM, respectively.
    HMGB1-IN-2
  • HY-155762
    Anti-neuroinflammation agent 1 2968412-77-1
    Anti-neuroinflammation agent 1 is a potent anti-neuroinflammation agent that regulates polarization BV2 microglia cells from M1 phenotype to M2 phenotype.
    Anti-neuroinflammation agent 1
  • HY-155772
    LUF7690 2941609-83-0
    LUF7690 (Compound 9) is a clickable and covalent affinity-based probe (AfBP) that targets the human A3AR (hA3AR). LUF7690 can be used in the detection and characterization of the hA3AR in different types of granulocytes, among other cell types.
    LUF7690
  • HY-155780
    Anti-inflammatory agent 52
    Anti-inflammatory agent 52 (compound 7j) is an orally active selective COX-2 inhibitor. Anti-inflammatory agent 52 has anti-HT29 transfer activity, which leads to periodic arrest in G2/M phase. Anti-inflammatory agent 52 has safety, moderate ability to suppress inflammation. Anti-inflammatory agent 52 has a rare property of suppressing the development of tumor in mouse model, showing anti-cancer activity.
    Anti-inflammatory agent 52
  • HY-155781
    Anti-inflammatory agent 53
    Anti-inflammatory agent 53 (compound 7c) is an orally active selective COX-2 inhibitor. Anti-inflammatory agent 52 has anti-HT29 transfer activity, which leads to periodic arrest in S phase and G2/M phase. Anti-inflammatory agent 52 has safety, moderate ability to suppress inflammation. Anti-inflammatory agent 52 has a rare property of suppressing the development of tumor in mouse model, showing anti-cancer activity.
    Anti-inflammatory agent 53
  • HY-155801
    CRX 527 216014-14-1
    CRX 527 is a ligand of TLR4 and also serves as an adjuvant for peptide-based cancer vaccines, showing potential to enhance anti-tumor immune responses. CRX 527 can also induce HSC differentiation, increase the proportion and quantity of LSK cells, and promote their differentiation into macrophages, activating immune defense and protecting intestinal epithelium from radiation damage.
    CRX 527
Cat. No. Product Name / Synonyms Application Reactivity